论文部分内容阅读
本文报道以恶性疟原虫子孢子和红内期裂殖子原虫重组蛋白为疫苗,对人体进行临床试验。在Ⅰ期实验中,研究了两种重组蛋白的安全性和免疫原性。其中,Ro 46-2717蛋白和Ro 46-2924蛋白分别由编码环子孢子(CS)蛋白及裂殖子表面抗原MSA-2的基因所衍生。这两种蛋白均在大肠杆菌中表达。用于试验的疫苗在每0.5ml的悬液中分别含上述重组蛋白100μg,氢氧化铝425μg,硫柳汞50μg。33名18—55岁的无疟史的瑞士健康志愿者在4周内未接受其他活疫苗接种。将疫苗注射在志愿者三角肌内,左侧注射环
This paper reports the P. falciparum sporozoite and the red-phase merozoite proto-recombinant protein vaccine for human clinical trials. In phase I experiments, the safety and immunogenicity of two recombinant proteins were studied. Among them, the Ro 46-2717 protein and the Ro 46-2924 protein were derived from the genes encoding the circumsporozoite (CS) protein and the merozoite surface antigen MSA-2, respectively. Both proteins are expressed in E. coli. The vaccine used for the test contained 100 μg of each of the above recombinant proteins, 425 μg of aluminum hydroxide, and 50 μg of thimerosal in every 0.5 ml of the suspension. Thirty-three healthy Swiss volunteers aged 18-55 with no history of malaria received no other live vaccination within 4 weeks. The vaccine was injected into the volunteers deltoid and the ring was injected on the left